|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, an intrachromosomal gene fusion between NAB2 and STAT6 was identified as the defining driving genetic event of SFT and different fusion types correlated with tumor histology and behavior.
|
27292373 |
2017 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
NAB2 exon 4-STAT6 exon 3 fusion correlated with classic SFT morphology and older age and showed a trend toward less mitotic activity; there was also a trend toward more aggressive behavior in tumors lacking NAB2 exon 4-STAT6 exon 3.
|
26883114 |
2016 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Another useful discovery was that the NAB2-STAT6 fusion is characteristic of solitary fibrous tumors.
|
26811225 |
2016 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, antibodies against the STAT6 C-terminal, are being used in paraffin-embedded tissues as a surrogate for identifying the NAB2-STA6 fusion gene which is considered a specific molecular marker for solitary fibrous tumor.
|
30072169 |
2018 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
A recurrent intrachromosomal rearrangement on chromosome 12q in solitary fibrous tumor leads to the formation of a NAB2-STAT6 fusion oncogene.
|
24457460 |
2014 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
While NAB2:STAT6 fusions are common in solitary fibrous tumors (SFT), we report this event for the first time in a newly diagnosed, secondary-type GBM or any other non-SFT.
|
26817999 |
2016 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Solitary fibrous tumors, which are characterized by their broad morphological spectrum and unpredictable behavior, are rare mesenchymal neoplasias that are currently divided into three main variants that have the NAB2-STAT6 gene fusion as their unifying molecular lesion: usual, malignant and dedifferentiated solitary fibrous tumors.
|
26022454 |
2015 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined six SN-HPCs and two sinonasal SFTs by immunohistochemistry and RT-PCR for NAB2-STAT6 fusions.
|
24807787 |
2014 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
NAB2-STAT6 gene fusion is a molecular characteristic of solitary fibrous tumors (SFT) and hemangiopericytoma, underscoring their definition as one diagnostic entity.
|
28128724 |
2017 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
It was suggested that a certain proportion of tumors previously diagnosed as malignant SFTs with high-grade nuclear atypia lacking NAB2-STAT6 should be categorized into a special subtype of SFT, which is genetically different from conventional SFTs, and which cannot be apparently distinguished from dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma.
|
25554652 |
2015 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathological data, including yearly follow-ups, are required for meningeal SFTs/HPCs to define the correlation of variants of NAB2-STAT6 fusion gene.
|
27271270 |
2016 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Solitary fibrous tumour (SFT) is an infrequently metastasising mesenchymal tumour defined by the <i>NAB2-STAT6</i> fusion gene.
|
29703757 |
2018 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
NAB2-STAT6 fusion was detected in 34 SFTs.
|
26686340 |
2016 |
|
hemangiopericytoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Most notable classification changes include: adding 'hybrid nerve sheath tumours' to the spectrum of benign nerve sheath tumours; an updated definition of atypical meningioma (WHO grade II), including cases with brain invasion; recognizing dural solitary fibrous tumour (SFT) and haemangiopericytoma (HPC) as a single tumour entity characterized by NAB2 and STAT6 gene fusions for which the term SFT/HPC was chosen; recognizing that pituitary granular cell tumour, spindle cell oncocytoma, and pituicytoma all share nuclear expression of TTF-1, possibly representing a spectrum of a single nosological entity derived from posterior pituitary glial cells.
|
28295484 |
2018 |
|
hemangiopericytoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
'Papillary' solitary fibrous tumor/hemangiopericytoma with nuclear STAT6 expression and NAB2-STAT6 fusion.
|
26746203 |
2016 |
|
hemangiopericytoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The finding that meningeal solitary fibrous tumors (SFTs) and meningeal hemangiopericytomas (HPCs) are both characterized by NAB2-STAT6 gene fusion has pushed their inclusion in the WHO 2016 Classification of tumors of the central nervous system (CNS) as different manifestations of the same entity.
|
29600523 |
2019 |
|
hemangiopericytoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The 2016 central nervous system (CNS) World Health Organisation (WHO) Update has merged the entities of meningeal solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into a single entity based on the presence of the nerve growth factor 1A (NGFI-A) binding protein 2 (NAB2)- signal transducer and activator of transcription 6 (STAT6) gene fusion in these tumors.
|
30233017 |
2019 |
|
hemangiopericytoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.
|
24513261 |
2014 |
|
hemangiopericytoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
We present two cases of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma (HPC) with immunohistochemistry of STAT6 and analysis of NAB2-STAT6 fusion genes.
|
25893823 |
2015 |
|
hemangiopericytoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
NAB2-STAT6 gene fusion is a molecular characteristic of solitary fibrous tumors (SFT) and hemangiopericytoma, underscoring their definition as one diagnostic entity.
|
28128724 |
2017 |
|
hemangiopericytoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathological data, including yearly follow-ups, are required for meningeal SFTs/HPCs to define the correlation of variants of NAB2-STAT6 fusion gene.
|
27271270 |
2016 |
|
Malignant neoplasm of prostate
|
0.120 |
PosttranslationalModification
|
disease |
BEFREE |
NAB2 and CDC6 were hypermethylated frequently in pCA (92%, 67%, respectively) and in BPH (91%, 59%, respectively).
|
16956712 |
2007 |
|
Malignant neoplasm of prostate
|
0.120 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that high levels of EGR1 coupled with low levels of NAB2 can result in high, unrestrained EGR1 transcriptional activity in human prostate cancers.
|
11567222 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Solitary fibrous tumors (SFTs) are NAB2-STAT6 fusion-associated neoplasms.
|
31321477 |
2019 |